A.O. Mater Domini Catanzaro
Welcome,         Profile    Billing    Logout  
 1 Trial 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tagliaferri, Pierosandro
ROME, NCT04591431 / 2018-002190-21: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Active, not recruiting
2
400
Europe
Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib
Fondazione per la Medicina Personalizzata
Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
12/24
06/25
CAPRI 2 GOIM, NCT05312398: Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen

Active, not recruiting
2
219
Europe
Cetuximab, Erbitux, FOLFIRI, FOLFOX regimen, FOLFOX, Irinotecan
University of Campania "Luigi Vanvitelli"
Metastatic Colorectal Adenocarcinoma
08/25
06/26

Download Options